Kenvue Inc. $KVUE Shares Sold by Cigna Investments Inc. New

Cigna Investments Inc. New cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 3.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,840 shares of the company’s stock after selling 634 shares during the period. Cigna Investments Inc. New’s holdings in Kenvue were worth $395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Fifth Third Bancorp lifted its position in Kenvue by 0.9% during the second quarter. Fifth Third Bancorp now owns 238,928 shares of the company’s stock valued at $5,001,000 after purchasing an additional 2,053 shares during the period. Wealth Advisory Solutions LLC acquired a new position in Kenvue during the second quarter valued at $340,000. CHICAGO TRUST Co NA acquired a new position in Kenvue during the second quarter valued at $452,000. Golden State Equity Partners raised its position in shares of Kenvue by 68.2% in the second quarter. Golden State Equity Partners now owns 43,299 shares of the company’s stock worth $906,000 after acquiring an additional 17,559 shares during the period. Finally, Arlington Partners LLC acquired a new position in shares of Kenvue in the second quarter worth about $2,110,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 3.9%

Shares of KVUE opened at $16.20 on Friday. The stock has a 50 day moving average price of $20.48 and a 200 day moving average price of $21.88. Kenvue Inc. has a one year low of $16.14 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a market capitalization of $31.09 billion, a price-to-earnings ratio of 21.89, a PEG ratio of 2.42 and a beta of 0.83.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.1%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is currently 112.16%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. UBS Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Barclays decreased their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Tuesday, July 15th. Canaccord Genuity Group decreased their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Bank of America decreased their price objective on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, July 15th. Finally, Citigroup reiterated a “neutral” rating on shares of Kenvue in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $23.32.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.